Amphastar Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amphastar Pharmaceuticals, Inc.
In addition to distributing to Target stores, TV, radio and digital advertising and late-2020 start of sales at Kroger stores are driving Primatene Mist sales growth. The epinephrine aerosol inhaler's sales increased 186% in 2020 to $51.7m and 47% in Q4 to $13.4m.
Amphastar announces that it has seven generic and three biosimilar products in development in order to target bigger markets. The company revealed that its insulin program is also developing towards interchangeable status.
The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.
Amphastar’s 2020 financial results included its best ever quarter and a different revenue pattern from most pharma and generic companies. Its evolving product mix and marketing campaigns were two reasons for its performance.
- Drug Delivery
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Amphastar France Pharmaceuticals (AFP)
- Armstrong Pharmaceuticals, Inc.
- International Medication Systems (IMS)
- Nanjing Puyan Pharmaceutical Technology (ANP)